. An antibody molecule links two hypervariable, antigen-binding domains (Fab fragments) via a flexible hinge to a constant region (Fc) . After anchoring to a foreign antigen, Fab fragments can mechanically neutralize pathogens by physically inactivating the viral entry machinery through blocking receptor binding, preventing necessary cleavage events or obstructing conformational changes that drive fusion of the pathogen and host membranes. Following Fab binding, the Fc domain links the target to the innate immune system to signal the presence of a threat and to mediate destruction of the foreign body or unhealthy cell. In the design of an immunotherapeutic agent, both ends of the antibody can be tailored to enhance antigen recognition by the Fab and to drive Fc-mediated immune responses in different directions, from dampened immunopathology ('silent Fc') to enhanced target clearance ('active Fc').
Characterization of Fab-mediated protection can be straightforward through the use of measurements of binding stoichiometry and neutralization of authentic viruses or pseudoviruses. Structural analysis of the binding of Fab domains to an antigen can define specific contacts that contribute to antigen recognition and antibody function.
In contrast, the measurement and visualization of Fc-mediated mechanisms is complex. Different functions can be orchestrated by Fc receptors (FcRs) expressed on different cells of the immune system, with each cell type able to deploy a unique set of anti-pathogen functions, such as cellular cytotoxicity, phagocytosis, direct pathogen killing and the modulation and/or stimulation of innate and adaptive immunity, which can be further influenced by the tissues or compartments in which they are activated. Indeed, FcRs marshal an incredible variety of anti-pathogen responses [8] [9] [10] . Further, those immune-system-stimulating Fc-FcR interactions have lower affinity than that of the often nanomolar Fab-antigen binding events or are more transient than the latter and instead rely on avidity to reach a threshold at which the identified target is marked for destruction. These avid interactions require that antibodies of different subclasses and isotypes compete for immunocomplex occupancy to collectively regulate binding and activation. Thus, polyclonal responses, rather than monoclonal responses, act in synergy to drive interactions involving larger complexes of proteins and cells that result in tiered signaling events that are difficult to directly observe by structural and biophysical techniques, although evolving methods such as correlation light electron microscopy could provide additional visual insights in the future 11, 12 . Despite the challenges that accompany the study of immune effector function, several examples from oncology and infectious disease have highlighted the importance of Fc activity by showing that the ability of an antibody to affect disease in animal models is dependent on Fc-mediated functions [13] [14] [15] [16] [17] [18] [19] [20] . For many infectious-disease targets, however, Fc-mediated clearance is or has been overshadowed by Fab-mediated neutralization, which is often the primary means by which mAb candidates are selected for immunotherapy. Thus, fewer non-neutralizing, celltargeting mAbs have been described or evaluated in animal models. Conflicting results from studies of filoviruses, which include ebolaviruses and marburgviruses, led us to critically examine the array of other antibody features and variables that, together with neutralization, correlate with in vivo protection. Our several-year, multidisciplinary analysis of antibodies to Ebola virus glycoprotein (GP), completed in 2018 (ref. 21 ), generated results that highlight the importance of Fc-mediated effector functions in post-exposure protection from infection with filovirus in animal models. Here we first describe the historical context in which the study began and how the findings relate to other contemporaneous work.
A combination of protection-driving variables
One of the first well-characterized mAbs to Ebola virus was KZ52, a human survivor antibody directed against Ebola virus GP 22 . KZ52, initially described in 1999, seemed to have the requisite features to be a successful immunotherapeutic directed against Ebola virus, including neutralization of Ebola virus in cell culture and highaffinity recognition of the receptor-binding core of Ebola virus GP 23 ( Fig. 1a) 24 . Nevertheless, passive delivery of KZ52 alone did not protect nonhuman primates (NHPs) against infection with Ebola virus, and the animals succumbed to disease. This lack of protection was not due to mutagenic escape; viruses isolated at time of death or euthanasia were sensitive to neutralization by KZ52 in vitro 25 . Furthermore, treated animals retained serum KZ52 titers of 200-400 μ g/ml at day 4 after infection, and concentrations were estimated to be more than 100-fold higher than the 90% infectious concentration (IC 90 ) at the time of challenge and for the first few days after exposure.
Optimism for the prospect of immunotherapy directed against Ebola virus increased when a study showed that polyclonal immunoglobulin G (IgG) concentrated from the serum of vaccinated and challenged NHPs was able to protect naive NHPs from infection with Ebola virus or the related Marburg virus 26 . Subsequently, two separate groups demonstrated that combinations ('cocktails') of mAbs could similarly achieve protection in primates. One protective cocktail, ZMAb 27, 28 , contains three mAbs 28 : mAb 1H3, which is poorly neutralizing and targets the glycan cap domain of the viral GP that is physically removed from the virion during entry into the cell, plus mAbs 2G4 and 4G7, which are both neutralizing. Interestingly, the epitopes for 2G4 and 4G7 on the GP molecule overlap the epitope for KZ52 29 (Fig. 1b) , and all three of these mAbs are susceptible to the same escape mutation in GP, which results in a change from glutamine to arginine at residue 508 21, 30 . The other cocktail, MB-003 31, 32 , also contains three mAbs: mAb 13C6, directed against the glycan cap 29, 33 , and mAbs 13F6 and 6D8, directed against the mucin-like domain 23, 34, 35 (Fig. 1c) . The observed protection of NHPs via MB-003 was thus somewhat surprising, as none of the component antibodies were strong neutralizers and all three antibodies target epitopes located on the upper and outer heavily glycosylated regions of GP that are cleaved from the virion during entry 36, 37 . Physical removal of these epitopes from virions before receptor binding probably explains the poor to lack of neutralization ability of the antibodies in cell culture. Their success in vivo, however, suggests that their protective ability might arise instead through Fc-mediated effector functions that tag GP-expressing virions and infected cells for destruction. Notably, whereas MB-003 comprising mAbs expressed in Chinese hamster ovary (CHO) cells offers poor protection to NHPs, MB-003 comprising mAbs produced in a plant-based system involving transgenic Nicotiana benthamiana results in better survival of NHPs following infection with Ebola virus. MB-003 expressed in these plant cells can also be used at a threefold lower dose 31, 38 . Transgenic N. benthamiana attach a truncated mammalian glycan of afucosylated and agalactosylated structure 39 , which enhances Fc-mediated cell-targeting functions [38] [39] [40] [41] [42] [43] [44] [45] [46] . Afucosylated antibodies, in particular, have 50-fold higher affinity for both Fcγ RIIIa and Fcγ RIIIb and increased antibody-dependent cell-mediated cytotoxicity (ADCC) activity 43, 44, [47] [48] [49] .Together, these early findings suggested that neutralization is not the sole predictor of in vivo success and that multiple mechanisms, including cell targeting by Fc, contribute to protection against Ebola virus.
In 2014, the six mAbs from the ZMAb and MB-003 cocktails were re-mixed to produce ZMapp, a cocktail that reverted advanced disease and conferred survival onto NHPs 50 . ZMapp combined mAbs 4G7 and 2G4 from ZMab 50 with mAb 13C6 from MB-003 ( Fig. 2a) and differed from the predecessor cocktails in two important ways. All three antibodies were chimerized to attach a human IgG1 Fc, rather than the original mouse IgG1 or IgG2a Fc, to the mouse Fab domains. Second, the component antibodies were produced in Nicotiana tobacco plant cells with afucosylated and/or agalatosylated glycans. The change in Fc structure and glycosylation might be linked to the cocktail's enhanced success relative to that of the earlier antibodies from which it was derived. ) (orange) that was produced in CHO cells for evaluation in rhesus macaques, at a dose of 50 mg per kg body weight (mg/kg), 1 day before and 4 days after viral challenge 25 . Throughout Figs. 1 and 2 , orange or yellow indicates mAbs that bind the GP core remaining after cathepsin-mediated cleavage; blue or purple indicates mAbs that bind the head and glycan cap. b, Superimposed negative-stain electron-microscopy structure of antibodies in the ZMAb cocktail 29 (orange, 2G4; yellow, 4G7; blue, 1H3) in complex with Ebola virus GP (gray). ZMAb antibodies were produced in mouse hybridoma cultures for evaluation in cynomolgus macaques, at a dose of 25 mg/kg, on days 1, 4 and 7 after challenge (100% survival) or days 2, 5, and 8 after challenge (50% survival) 28 . c, Model of the MB-003 cocktail, made from the negative-stain electron-microscopy structure of the 13C6-GP complex 29 and the crystal structure of 13F6 (purple molecular surface) bound to its mucin-like domain linear epitope 123 (white ball-and-stick). The mAbs in MB-003 were produced in CHO or Nicotiana cells and were evaluated in rhesus macaques, at a dose of 50 mg/kg (produced in CHO cells; 50% survival) or 16.7 mg/kg (produced in Nicotiana cells; 100% survival), at 1 hour and 4 and 7 days after challenge 31 . Delivery of Nicotiana-produced MB-003 at later time points (5, 7 and 10 days after challenge) resulted in 43% survival 32 . No high-resolution structural information exists so far for the mucin-like domain or MB-003 component 6D8 (modeled with gray circles and a purple Fab fragment, respectively, here). The relative positions of the two mucin-binding antibodies 13F6 and 6D8 are as yet unknown. ) (blue) in complex with Ebola virus GP, and its dosage schedule for rhesus macaques, which received a dose of 50 mg/kg on days 5, 6 and 7 (ref. 51 ). c, The REGN-EB3 cocktail, which contains mAbs 3470, 3471 and 3479, visualized by negative-stain electron microscopy, and dosage schedule for rhesus macaques 52 . REGN-3B3 was evaluated in three-dose and single-dose regimens.
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Two novel human antibody therapies have now also been placed on the World Health Organization's list of investigational therapies for use in the outbreaks of Ebola virus disease in the Democratic Republic of the Congo in 2018 (http://www.who.int/emergencies/ ebola/MEURI-Ebola.pdf?ua= 1). These include a mAb monotherapy from the National Institute of Allergy and Infectious Diseases (NIAID) (mAb 114; also known as VRC 608) 51 ( Fig. 2b ) and a threemAb cocktail from Regeneron (REGN 3470-REGN 3471-REGN 3479; also known as REGN-EB3) 52 ( Fig. 2c ). Both mAb 114 and REGN-EB3 greatly promote the survival of NHPs when delivered 5 days after exposure to Ebola virus. mAb 114 demonstrates both neutralization and Fc-dependent cell-targeting activities in vitro 51 . In the study by the consortium (VIC) that is described in greater detail below, all but one of the antibodies in the GP1 head-binding epitope group to which mAb 114 belongs exhibit both neutralization and cell-targeting functions 21 . Thus, the head epitope seems to exist at the physical intersection of the regions of GP that drive neutralization and the regions of GP that exhibit greater activation of phagocytosis and natural killer (NK) cells than that of other epitope classes.
In contrast to the mAb 114 monotherapy, the three mAbs in REGN-EB3 provide complementary activities across the three antibody footprints. One component, REGN 3479, recognizes the conserved GP2 fusion loop and is neutralizing. A second component, REGN 3471, recognizes the outer glycan cap and has cell-targeting functions. The third, REGN 3470, binds the GP1 head and offers both neutralization and cell-targeting activities, including Fcγ RIIIa and other Fcγ R-related functions 52 . Thus, all three candidate immunotherapeutic treatments for Ebola virus incorporate a mixture of neutralizing and cell-targeting functions and bind to a mixture of neutralizing and cell-targeting epitopes (Fig. 2c) . For NHP studies, these newer candidate therapies were produced in 293Freestyle cells (mAb 114) 51 and modified CHO cells (Regeneron) 52 .
A comprehensive study
In 2012, after the first protection results were described, we wondered if the neutralizing but non-protective mAb KZ52 and the poorly neutralizing but more protective mAb MB-003 were outliers or had features typical of many antibodies. We aimed to better determine, on a more statistically relevant scale, what kinds of antibodies or antibody features correlate with protection in animal models of infection with Ebola virus. We also wondered what in vitro assays would best forecast in vivo protection, information that could streamline the research pipeline for faster identification or rational design of candidate therapeutics. Cognizant that each research group has their own assays and criteria for identifying, 'down-selecting' and producing antibodies, and that understanding of the range of antibody activity was needed, researchers in the filovirus field pooled their intellectual and physical resources into a single collaborative study. Over 43 academic, industry and government laboratories across five continents united to form the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC) 53 , supported by a 'Center of Excellence in Translational Research' grant from the NIAID. This consortium performed a large, multidisciplinary study of antibodies to filovirus that were isolated by multiple laboratories and produced by multiple methods. Some participating research laboratories contributed one favorite antibody or a few favorite antibodies (often selected on the basis of neutralization), while other groups contributed a larger array of different samples. All antibodies were provided coded identifiers to protect the investigators' ability to publish findings from their own antibodies, many of which were not yet described in the literature.
This project, completed in 2018 21 , analyzed 171 donated mAbs across a battery of in vitro and in vivo assays encompassing biochemistry, structural biology, glycan sequencing, neutralization, measurement of immune effector functions, and protection in the mouse model, for each antibody in the study pool. Epitopes were determined by ELISA and structural biology at Scripps Research and by alanine scanning at Integral Molecular. The neutralization activity of each mAb in the panel was measured by three different assays involving the following: authentic Ebola virus, at biosafety level 4 (BSL-4) (United States Army Medical Research Institute of Infectious Diseases (USAMRIID)); a biologically contained Ebola virus (Δ VP30) for which an essential replication complex component, VP30, is expressed in trans, at BSL-2 to BSL-3 (University of Wisconsin) 54 ; and recombinant vesicular stomatitis virus (rVSV) engineered to display Ebola virus GP on its surface, at BSL-2 (Albert Einstein College of Medicine). For the rVSV assay, the fraction of viral particles left un-neutralized at maximal antibody concentration was also analyzed 55 . In the rVSV and Δ VP30 systems, infected cells were quantified through the use of a reporter gene inserted into the pseudoviral genome. In the authentic Ebola virus assay, infected cells were quantified by detection of the binding of mAb KZ52.
For immune effector function, seven parameters for each of the 171 mAbs were evaluated: the ability of human and mouse phagocytes and neutrophils to engulf particles bearing Ebola virus GP trimers after incubation with a given mAb (four different measurements); and the ability of each mAb to activate human NK cells (three measurements: cell-surface expression of lysosome marker CD107a and secretion of the inflammatory chemokine MIP1-β (CCL4) and the cytokine IFN-γ 56, 57 ). Protection was evaluated in the mouse model of infection with Ebola virus at both USAMRIID and the Public Health Agency of Canada. For measurement of protection, groups of ten mice were infected with mouse-adapted Ebola virus and were treated 2 days after infection with a given mAb from the panel. Survival and body weight were monitored for 28 days, and the proportion of mice that survived was determined. The mAbs that resulted in the survival of six or more mice (60%) were deemed protective. Machinelearning approaches at Scripps, Ragon and the Los Alamos National Laboratory established correlation networks illustrating how antibody features related to each other and to in vivo protection in the mouse model 21 . Several relationships were clear. First, epitopes linked to the neutralization of virions in cell culture are located predominantly on the receptor-binding core of the GP that is retained during viral entry (Fig. 3a) . Second, epitopes in the study linked to maximal phagocytic functions are located predominantly in the uppermost regions of GP, including the head, glycan cap and mucin-like domains (Fig. 3b) . However, antibodies with strong NK cell activity are distributed more broadly across the GP surface.
The physical clustering of neutralization-linked epitopes on the GP core and phagocytosis-linked epitopes on the upper, heavily glycosylated domains suggests that neutralization functions operate on virion-surface GP, while Fc-mediated phagocytic functions operate on cell-surface GP on infected cells (Fig. 3c) . Fc-mediated functions of NK cells are spread more broadly. Those mAbs that anchor to the GP core might interfere with steps involved in viral entry, such as receptor binding, cathepsin-mediated cleavage, and fusion [58] [59] [60] [61] . In contrast, antibodies bound to glycan cap and mucinlike domain epitopes on virion-surface GP would be removed by the cathepsin-mediated cleavage of GP in the endosome 37,62-65 but would remain on GP molecules displayed on the surface of infected cells. Enhanced phagocytic activity by antibodies bound to these upper regions might result from their greater accessibility to FcRs and/or greater structural flexibility at these epitopes that facilitates multivalent binding, Fc-Fc interactions and recruitment of immune cells.
The glycan cap and some GP1 head epitopes are also found on an abundantly secreted dimeric form of the GP called 'sGP' . The . Unexpectedly, across the panel of mAbs in the VIC study, cross-reactivity with sGP was neither beneficial nor detrimental to the ability of an antibody to offer protection. Furthermore, those mAbs that cross-reacted with sGP unexpectedly performed similarly in neutralization assays, whether sGP was present in wild-type amounts (authentic Ebola virus and Δ VP30 Ebola virus) or was absent (rVSV). We note that in the VIC study, sGP-cross-reactive antibodies were able to activate FcR-bearing immune cells. Since sGP is secreted from infected cells, such sGP-containing immunocomplexes would not directly tag infected cells for destruction but could form immunocomplexes that stimulate protection in other ways.
We opted to revert to the original identifiers for mAb KZ52 and the mouse versions of mAbs 13C6, 2G4 and 4G7 to provide reference points. KZ52 is VIC 136 (a human IgG1) and was produced for this study in CHO cells 25 . 4G7 and 2G4 in their original mouse versions are VIC 18 and VIC 24 (mouse IgG2a and IgG2b, respectively) and were produced in hybridoma culture.
In the VIC study, mAbs KZ52, 2G4 and 4G7 all exhibited equivalent neutralization activity but had lower effector-function scores, including two of seven possible Fc-mediated functions, than those of other antibodies analyzed. In contrast, cell-targeting activity of the ZMapp versions of 2G4 and 4G7 was probably improved by the glycan modifications afforded by their production in Nicotiana 50 .
Correlates of in vivo protection
In the overall VIC study of those and other antibodies in the field, the expectation, on the basis of published work on human immunodeficiency virus type 1 and other viruses, was that neutralization would be a strong forecaster of protection [67] [68] [69] [70] [71] [72] . Of the 171 mAbs in the VIC panel, 20 (12%) achieved robust neutralization in every assay and also conferred strong levels of protection in the mouse model. Measures of neutralization were the strongest univariate predictors of protection in the study (ρ = 0.61-0.68). Neutralization alone, however, was an incomplete predictor of in vivo success. Eight mAbs in the study (5%) achieved potent and robust neutralization but failed to provide protection in vivo. Another nine mAbs in the study (5.4%) achieved poor or no neutralization yet did provide protection in vivo (Fig. 4) . Of those nine, three offered high levels of in vivo protection in the absence of any measurable neutralization in any assay. The remaining six achieved neutralization in some assays, albeit weakly (a reduction of only 55% in infected cells at a dose of 20 μ g/ml, compared with the reduction of 99.5% in infected cells at a dose of 0.5 μ g/ml by more robustly neutralizing samples). For these nine antibodies, the ability to confer postexposure protection in the mouse model was not predicted by their ability to achieve neutralization in vitro.
We note that researcher choice in antibody selection could have biased the composition of the pool of mAbs in the VIC study. In vitro neutralization followed by in vivo protection in a mouse model are the two most common primary initial selection criteria in filovirus research. Those labs that contributed just a few antibodies tended to contribute neutralizing antibodies. We would expect that those neutralizing antibodies already known to successfully provide in vivo protection would be more likely to be contributed to the study than neutralizing antibodies already known to fail in providing in vivo protection. Such selection processes could amplify apparent correlations of neutralization to protection in our results. Furthermore, if most labs first winnowed antibodies on the basis in vitro neutralization activity, those antibodies that provide protection without strong neutralization would not have been identified or contributed. As a result, the ~5% population of the VIC mAbs that seemed to succeed mainly through cell-targeting Fc functions could be an under-representation of what is produced during an authentic polyclonal response. In addition, cell-targeting, non-neutralizing antibodies might function better in concert than alone, a feature particularly relevant for polyclonal antibodies elicited by vaccination or natural infection. Thus, the analysis of single mAbs might have further undervalued the therapeutic potential of Fc-mediating antibodies.
Notably, the performance of antibodies for which neutralization did not adequately forecast protection could be linked to the presence or absence of NK cell activity and other Fc-mediated functions. All antibodies in the VIC study that achieved good neutralization 
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NAtuRE ImmuNology but failed to provide protection in vivo also registered scores of NK cell activity ranging from zero to low (Fig. 4) . All antibodies in the study that achieved little or no neutralization but did provide protection in vivo registered high positive scores in driving NK and/or phagocytic functions. The VIC study suggests that evaluating and enhancing antibody-mediated NK functions should be key goals of immunotherapeutic efforts. Published work in this research field has further emphasized the importance of Fc-mediated cell-targeting functions. Notably, in several studies of vaccines against Ebola virus, total binding antibody, rather than neutralizing antibody, has been the strongest correlate of protection [73] [74] [75] . Total binding antibody would by definition include the fraction that operates via cell-targeted Fc functions. Another study of three newly described mAbs directed against Ebola virus found that the protection they provided in the mouse model correlated with their ability to confer ADCC, not with their neutralization capacity 76 . These antibodies were functional only in wild-type mice bearing NK cells, not in NK cell-deficient mice. The additional link to enhanced NK cell activity confirms evidence from natural infection: fatal Ebola disease is associated with lower NK cell function than that of survivable disease 77 .
In the comprehensive VIC study described above and in other contemporaneous work, we thus note a spectrum of antibody activity. At one end of the spectrum are those antibodies that achieve protection by effector mechanisms alone. Nearly all of these mAbs target the upper and outer regions of the viral GP, and their physical position might facilitate access of the antibody to FcR-bearing cells and also promote multivalent binding, as well as the decoration of infected cells, circulating virions or even secreted forms of sGP for activation of the immune system. At the other end of the spectrum are potent neutralizing antibodies that provide protection in the absence of effector activity. These antibodies might provide protection via Fab-mediated mechanical inactivation of the entry GP alone. Many of these antibodies bind to the GP core, in the middle to lower (membrane-proximal) tiers of the structure. Some of these epitopes might prevent access to effector cells, and thus engineering to enhance effector function might or might not improve their performance. In the middle of the spectrum are antibodies that exhibit a variety of features, with a range of neutralization and effectorfunction strength.
Our immunological effector assays were performed in a highthroughput standardized format to characterize the immunological functions of all 171 mAbs in the VIC panel. Since the way that the GP trimer is displayed on beads may differ from that on cells, assays using GP-transfected or Ebola virus-infected cells are now in progress. Nonetheless, results from these high-throughput screens go beyond mere antibody affinity for GP to correlation with experimental protection in the mouse model. Moreover, antibodies that elicit an array of effector functions often have moderate affinity for GP, whereas those antibodies that lack apparent effector function and provide protection via mechanical neutralization tend to have higher affinity for GP.
A major limitation of the VIC study is that the in vivo protection results were obtained in the BALB/c mouse model. The apparent importance of effector functions of vaccines and immunotherapies tested in humans and NHPs, however, suggests that some of these general findings obtained with the mouse model will translate to higher animals. However, the degree to which protection in the BALB/c mouse model compares with protection in larger animal models, such as guinea pigs, ferrets or NHPs, or even alternative mouse models, such as those expressing human FcRs [78] [79] [80] [81] , awaits systematic study. FcR-mediated mechanisms of protection are expected to differ among animal models, because guinea pigs, NHPs and humans have evolved analogous but often discrete Fc-FcR systems with varying affinity for different antibody-FcR combinations. Indeed, mice lack both Fcγ RIIA and Fcγ RIIIB, the latter of which is expressed on neutrophils in humans 82 . Mechanical neutralization solely due to Fab binding, which requires only a strict biophysical Nine antibodies (left; VIC identifiers at top) protected ≥ 60% of mice yet achieved little to no neutralization (a neutralization score of 0 (no neutralization measured at all in any assay) to 1 (weak neutralization measured in one assay and no neutralization measured in the other three) or 2 (strong neutralization in only one assay)). Seven of these nine recognize tier 1 or unknown epitopes. Eight antibodies (right; VIC identifiers at top) protected ≤ 30% of mice despite their relatively strong neutralization scores of 5-7. These antibodies typically achieved at least moderate, and often potent, neutralization, in all four measures, and recognize tier 2 and tier 3 epitopes. Numbers in boxes represent the average polyfunctionality, neutralization score and protection value for the protective but poorly neutralizing group (left) and the neutralizing but poorly protective group (right). Vertical columns of boxes represent polyfunctionality, immune effector function score, overall neutralization and protection (indicated by color rather than an absolute value; key at right). Polyfunctionality (top row) is a sum of 'yes' or 'no' responses for each of the seven effector functions measured (below), including markers of both phagocytosis and NK cell function (left margin); one point was assigned for strong or moderate activity on each of the seven 'readouts', with a maximum score of 7. Antibody neutralization scores were calculated with 2, 1, or 0 points assigned for strong activity, moderate activity, and weak or no activity, respectively, on the four neutralization 'readouts', for a maximum score of 8. Bottom, epitopes for each antibody (key at right; GP1/2 indicates GP1 and GP1).
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interaction between virus and antibody to confer protection, probably translates more faithfully from cell culture to rodents and to primates, perhaps reinforcing initial down-selection via neutralization. In other words, antibodies that function mainly by physical, Fab-mediated blockade might have been easier to identify because they do not require immune functionality, which is, as yet, more difficult to recapitulate in vitro and across animal models. The findings of the VIC study strongly suggest that immune effector function must also be considered in the development of immunotherapeutics and for capitalizing on the full repertoire of immunological options available. Better bridging methods must be developed for the study of antibodies for use in humans, across rodent and other non-human species used for in vivo evaluation. Given the potential differences among animal models and the effector functions themselves, systematic comparison of different antibodies that achieve protection by different mechanisms, assessed across the standard animal models in use in filovirus research is needed. Such analyses would contribute to the understanding of the relative factors that contribute to protection in each animal model, as well as the role of immune effector function. Our previous expectation prompted the assumption that immunotherapies should focus on neutralizing antibodies. However, the existence of a class of antibodies that probably achieve protection via their Fc alone indicates that complementary or alternative routes to protection are underappreciated and insufficiently understood. The identification of antibodies that mediate protection through immune effector function would facilitate delineation of the specific Fc features and geometry of Fc recognition that lead to protection and would elucidate Fc-engineering strategies that could improve protection by these and neutralizing antibodies alike.
relevance of glycan modifications on antibodies
A common assumption about antibody production is that all antibodies produced in vitro will be glycosylated similarly and will faithfully represent the profiles that can be generated in vivo. However, more than two decades of research into monoclonal therapy has pointed to major differences, in terms of glycosylation, among recombinant antibodies produced within expression systems based on 293T human embryonic kidney cells or across those based on CHO cells or hybridomas, all of which probably do not reflect the original glycan profile that might have been present on the original antibody. Differences in culture conditions, cell quality, medium content and even transfection conditions result in substantial changes in glycan content observed even within the same production laboratory [83] [84] [85] . Across the mAb panel of the VIC study, we observed significant heterogeneity in glycan content across the 19 glycan structures that we measured 21, 86 , even among the 94 human IgG1 mAbs produced in traditional mammalian cell lines. We wondered how glycan structure, across the VIC pool, influenced the induction of different effector functions.
We used an unbiased hierarchical clustering algorithm to group antibodies by glycan content alone; this resulted in 17 different clusters (Fig. 5a) . As a comparison, we also used unsupervised principal-component analysis of glycan content (Fig. 5b) , which also separated the antibodies into these 17 clusters, or 17 distinct glycan profiles. To visualize the average glycan profile of the antibodies within each cluster, we generated a heat map depicting the glycan content of each cluster: average total galactose content (categorized as G0, G1 and G2), fucose, bisection by N-acetylglucosamine, and sialic acid (Fig. 5c) . Next, to determine if the different clusters resulted in different functional antibody profiles, we plotted the average effector functional response of each cluster as high activity, medium activity, or low or no activity (Fig. 5d) . Notably, several clusters were characterized by high functionality (clusters 1, 3, 11 and 12), whereas others were characterized by low activity (cluster 7) or limited functional diversity (clusters 4, 5, 9, 10, 13 and 17).
Of note, the highly functional clusters (1, 3, 11 and 12) represent different glycan profiles: afucosylated and/or agalactosylated (clusters 1 and 3) and mono-galactosylated, bisected glycan profiles (clusters 11 and 12). Each profile has been independently associated with enhanced effector function [87] [88] [89] . In contrast, clusters with low or limited functionality were characterized predominantly by a greater content of fucose in combination with sialic acid (clusters 7, 8 and 9), which suggested that these glycans might hinder effector functionality. While afucsoylation was clearly linked to enhanced FcR function, additional glycan changes were also linked to unique functional and polyfunctional profiles. These known, and perhaps other, unexplored glycan profiles naturally and actively leverage FcRs to drive enhanced functionality. Thus, the selection of a production cell line and evaluation of the resulting antibody glycans should be considered in order to maximize functional activity by therapeutic antibodies. Systematic and comprehensive mapping of the individual Fc-glycan functional profiles might provide a roadmap with which to improve protection in next-generation therapeutic design.
Strategy going forward
Overall, the finding that a relatively large number of antibodies to Ebola virus GP can confer protection either solely or significantly through effector mechanisms was unexpected. Moreover, the number of effector-driven antibodies in the VIC panel suggests that lack of neutralization does not necessarily indicate a lack of protective activity. The antibodies that strongly drive such effector functions, together with control antibodies that do not, will comprise focused sets for further study. These study sets will allow the delineation of which immune effector functions are important and determination of how the importance of particular functions differs by the epitope recognized (e.g., upper versus lower on the viral antigen) and if the significance of effector function is retained in other animal models.
How should protective antibodies be identified in the first place? The VIC study indicates that in a rapid selection process intended to identify potential therapeutic candidates quickly, viral neutralization in cell culture is indeed an effective down-selection mechanism. Therefore, if time permits only one assay, neutralization alone would probably provide an effective 'rough cut' and would probably identify features that can translate from in vitro studies to in vivo studies. Indeed, if antibodies had been selected among the VIC pool on the basis of neutralization alone, 60% of the protective antibodies would have been selected. However, if the VIC pool had instead been initially downselected on the basis of Fc polyfunctionality (i.e., sum of the scores for the seven separate immune effector measures), about 60% of the protective antibodies would similarly have been selected. A twopronged selection approach, using both neutralization and Fc function, would have predicted 96% of the protective antibodies.
The ability of an antibody to promote the killing of infected cells should be actively sought in antibody-discovery programs, rather than being simply a parallel feature during in vivo testing. We have found, in particular, that NK cell effector function is probably the feature that tips the balance in favor of a greater likelihood of protection. Screens for NK cell activity and substitutions to enhance NK cell activity might be particularly effective in identifying and enhancing protective activity. Better understanding of how to evaluate large panels of antibodies for Fc-mediated protection could reduce the number of animals required for eventual in vivo experimentation and would support the three 'Rs' of in vivo research: replacement, reduction and refinement 90 . Although Fc-mediated protection is more challenging to understand in vitro and might not readily translate from cell culture to various animal species, such functions can be engineered through the use of well-characterized point mutations that affect FcR affinity and the type of glycan modification 8, 10, 91 . Alterations to the https://doi.org/10.1038/s41590-018-0233-9
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Fc, such as the substitutions L234A and L235A 92 or G236R and L236R 93, 94 , or deletion of the glycosylation sequon at Asn297 95, 96 , diminish effector function. Modification of the glycan linked to Asn297 can enhance function. Diminished fucosylation and the addition of bisecting N-acetylglucosamine improve ADCC 91, 97 , and several afucosylated therapeutic antibodies have been approved for or are in human clinical trials for oncology applications [98] [99] [100] [101] . Amino-acid substitutions in the Fc, such as S239D and I332E 102 , E345R 103 and others 8, 102, [104] [105] [106] , increase the affinity of Fc for Fcγ RIIa, Fcγ RIIIa and complement and also enhance cell targeting. Many antibodies bearing those substitutions have also advanced to clinical trials for oncology [107] [108] [109] [110] [111] [112] . Substitutions such as S267E, H268F and S324T, which improve affinity for the complement component C1q, and substitutions such as E345K or E340G, which enhance IgG hexamerization 103, 113 , stimulate complement-dependent cytotoxicity. Other substitutions, such as M252Y, S254T and T256E 114 , or M428L and N434S 115 , extend antibody half-life. Engineered antibodies to Staphylococcus aureus α -toxin 116 and human immunodeficiency virus type 1 117 bearing these substitutions have been evaluated in clinical trials. In contrast to the well-characterized Fc modifications, Fab-mediated neutralization is difficult to engineer, and there are no universal point substitutions that can confer neutralizing activity onto a non-neutralizing antibody. However, the attachment of an engineered Fc to a potently neutralizing Fab could improve its in vivo performance by enhancing the targeting and destruction of infected cells so they do not continue to be viral factories and by increasing its potential bioactivity at a lower concentration than that required for long-term protection and control. Which Fc modifications are ideal and whether the optimal modifications differ according to the epitope on Ebola virus GP remain unclear.
Information gathered from studying the antibodies discussed here will help characterize which specific features beyond neutralization increase in vivo efficacy of antibodies and will provide roadmaps for the rational engineering and improvement of immunotherapeutic agents. Greater understanding of the features of these non-neutralizing yet highly protective samples might also result in strategies with which to identify such antibodies in the serum of people who have been vaccinated. Such studies could be broadly applicable, as published work suggests that the induction of celltargeting antibodies is desirable for protection against a variety of pathogens that threaten human health [118] [119] [120] [121] [122] , particularly when neutralizing antibodies are difficult to elicit. FOCUS | PersPective
